SLNO (Soleno Therapeutics) Beginning Cash Position : $57.02 Mil (As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Soleno Therapeutics Beginning Cash Position?

Soleno Therapeutics's Beginning Cash Position for the quarter that ended in Sep. 2024 was $57.02 Mil.

Soleno Therapeutics's quarterly Beginning Cash Position declined from Mar. 2024 ($169.68 Mil) to Jun. 2024 ($42.85 Mil) but then increased from Jun. 2024 ($42.85 Mil) to Sep. 2024 ($57.02 Mil).

Soleno Therapeutics's annual Beginning Cash Position declined from Dec. 2021 ($49.22 Mil) to Dec. 2022 ($21.30 Mil) and declined from Dec. 2022 ($21.30 Mil) to Dec. 2023 ($14.60 Mil).

Soleno Therapeutics Beginning Cash Position Historical Data

The historical data trend for Soleno Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Soleno Therapeutics Beginning Cash Position Chart

Soleno Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

23.10

20.73

49.22

21.30

14.60

Soleno Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Beginning Cash Position	Get a 7-Day Free Trial															19.37	52.44	169.68	42.85	57.02

Soleno Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Soleno Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Soleno Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Soleno Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soleno Therapeutics Inc (NAS:SLNO) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

6XC:Germany

Address

203 Redwood Shores Parkway, Suite 500, Redwood City, CA, USA, 94065

Website

https://www.soleno.life

Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.

Executives

Bhatnagar Anish	director, officer: See Remarks	3 TWIN DOLPHIN DRIVE, SUITE 160, REDWOOD CITY CA 94065
Kristen Yen	officer: See Remarks	3 TWIN DOLPHIN DRIVE, SUITE 160, REDWOOD CITY CA 94065
Patricia C Hirano	officer: See Remarks	1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065
James H Mackaness	officer: Chief Financial Officer	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Vivo Opportunity Fund Holdings, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Vivo Opportunity, Llc	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Abingworth Bioventures Vii Lp	10 percent owner	PRINCES HOUSE, 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Matthew Pauls	director	9 DEER PARK DRIVE, SUITE C, MONMOUTH JUNCTION NJ 08852
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Llp Abingworth	10 percent owner	38 JERMYN STREET, LONDON X0 SW1Y 6DN
Jack W Schuler	10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Carlyle Holdings I L.p.	10 percent owner	C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Carlyle Holdings I Gp Sub L.l.c.	10 percent owner	C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505